PROCEPT BioRobotics Corporation

NasdaqGM:PRCT Stock Report

Market Cap: US$2.7b

PROCEPT BioRobotics Future Growth

Future criteria checks 2/6

PROCEPT BioRobotics is forecast to grow earnings and revenue by 38.3% and 24.2% per annum respectively while EPS is expected to grow by 41.8% per annum.

Key information

38.3%

Earnings growth rate

41.8%

EPS growth rate

Medical Equipment earnings growth16.2%
Revenue growth rate24.2%
Future return on equityn/a
Analyst coverage

Good

Last updated18 Apr 2024

Recent future growth updates

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Recent updates

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05
The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07
Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14
Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27
Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Procept Biorobotics announces $52M debt refinancing

Oct 10

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems

Sep 19

Procept BioRobotics Has Resources To Ramp Up Commercialization

Sep 01

Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment

May 26

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10
Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target

Mar 10
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target

Earnings and Revenue Growth Forecasts

NasdaqGM:PRCT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026382-44N/AN/A5
12/31/2025295-77N/AN/A8
12/31/2024210-103-96N/A8
12/31/2023136-106-133-108N/A
9/30/2023116-107-126-108N/A
6/30/2023102-105-122-109N/A
3/31/202385-98-106-98N/A
12/31/202275-87-83-80N/A
9/30/202261-77-74-72N/A
6/30/202250-69-65-65N/A
3/31/202241-64-61-60N/A
12/31/202134-60-58-57N/A
9/30/202128-57-55-54N/A
6/30/202121-55-53-52N/A
3/31/202114-53-52-52N/A
12/31/20208-53-49-48N/A
12/31/20196-42-51-44N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRCT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PRCT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PRCT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PRCT's revenue (24.2% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: PRCT's revenue (24.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PRCT's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.